CR20150530A - Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina - Google Patents

Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina

Info

Publication number
CR20150530A
CR20150530A CR20150530A CR20150530A CR20150530A CR 20150530 A CR20150530 A CR 20150530A CR 20150530 A CR20150530 A CR 20150530A CR 20150530 A CR20150530 A CR 20150530A CR 20150530 A CR20150530 A CR 20150530A
Authority
CR
Costa Rica
Prior art keywords
spiroindoline
derivatives
liberator
gonadotropine
antagonists
Prior art date
Application number
CR20150530A
Other languages
English (en)
Inventor
Olaf Panknin
Sven Ring
Stefan BÄURLE
Andrea Wagenfeld
Reinhard Nubbemeyer
Katrin Nowak-Reppel
Gernot Langer
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48047908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150530(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CR20150530A publication Critical patent/CR20150530A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Derivados de espiroindolina, procesos para supreparación y composiciones farmacéuticas con los mismos, suuso para el tratamiento de enfermedades y su uso en laelaboración de medicamentos para el tratamiento deenfermedades, en especial enfermedades relacionadas con lashormonas sexuales, tanto en hombres como en mujeres.
CR20150530A 2013-04-09 2015-10-09 Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina CR20150530A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13162986 2013-04-09
PCT/EP2014/057079 WO2014166958A1 (en) 2013-04-09 2014-04-08 Spiroindoline derivatives for use as gonadotropin-releasing hormone receptor antagonists

Publications (1)

Publication Number Publication Date
CR20150530A true CR20150530A (es) 2016-01-29

Family

ID=48047908

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150530A CR20150530A (es) 2013-04-09 2015-10-09 Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina

Country Status (28)

Country Link
US (1) US20160052936A1 (es)
EP (1) EP2984092A1 (es)
JP (1) JP2016519104A (es)
KR (1) KR20150139917A (es)
CN (1) CN105308053A (es)
AP (1) AP2015008822A0 (es)
AR (1) AR095785A1 (es)
AU (1) AU2014253232A1 (es)
BR (1) BR112015025700A2 (es)
CA (1) CA2908869A1 (es)
CL (1) CL2015003013A1 (es)
CR (1) CR20150530A (es)
CU (1) CU20150141A7 (es)
DO (1) DOP2015000259A (es)
EA (1) EA201501000A1 (es)
HK (1) HK1216101A1 (es)
IL (1) IL241067A0 (es)
MA (1) MA38463B1 (es)
MX (1) MX2015014267A (es)
NI (1) NI201500149A (es)
PE (1) PE20160007A1 (es)
PH (1) PH12015502318A1 (es)
SG (1) SG11201506962TA (es)
TN (1) TN2015000453A1 (es)
TW (1) TW201518304A (es)
UY (1) UY35526A (es)
WO (1) WO2014166958A1 (es)
ZA (1) ZA201508209B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018224498A1 (en) 2017-06-05 2018-12-13 ObsEva S.A. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0213715D0 (en) * 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
PE20141699A1 (es) * 2012-01-16 2014-11-29 Bayer Ip Gmbh Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina

Also Published As

Publication number Publication date
CN105308053A (zh) 2016-02-03
EP2984092A1 (en) 2016-02-17
MA38463A1 (fr) 2018-05-31
NI201500149A (es) 2015-11-30
MX2015014267A (es) 2016-03-01
EA201501000A1 (ru) 2016-04-29
TN2015000453A1 (en) 2017-04-06
IL241067A0 (en) 2015-11-30
PH12015502318A1 (en) 2016-02-15
TW201518304A (zh) 2015-05-16
SG11201506962TA (en) 2015-10-29
AR095785A1 (es) 2015-11-11
US20160052936A1 (en) 2016-02-25
JP2016519104A (ja) 2016-06-30
PE20160007A1 (es) 2016-02-14
BR112015025700A2 (pt) 2017-07-18
AP2015008822A0 (en) 2015-10-31
HK1216101A1 (zh) 2016-10-14
WO2014166958A1 (en) 2014-10-16
CA2908869A1 (en) 2014-10-16
UY35526A (es) 2014-11-28
DOP2015000259A (es) 2015-11-15
KR20150139917A (ko) 2015-12-14
CL2015003013A1 (es) 2016-04-08
ZA201508209B (en) 2018-05-30
MA38463B1 (fr) 2018-11-30
CU20150141A7 (es) 2016-03-31
AU2014253232A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
CL2016000922A1 (es) Derivados de anillo bicíclico fusionado piridilo como inhibidores fgfr4
CR20160501A (es) Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa
GT201400153A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
CL2018001171A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CL2015000530A1 (es) Compuestos derivados ciclicos eter pirazol-4-il-heterociclil-carboxamida, como inhibidores de la quinasa pim; composicion farmaceutica que los comprende; y su uso para el tratamiento de cancer, trastornos inmunologicos, enfermedades cardiovasculares, infeccion virica, inflamacion, trastornos del metabolismo/funcion endocrina y trastornos neurologicos.
AR102712A1 (es) Agonistas parciales del receptor de insulina
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
UY36779A (es) Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
UY36179A (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagón
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
CO2017002160A2 (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
CL2016001151A1 (es) Derivados de purina 2,6-sustituidos y su uso en el tratamiento de trastorno proliferativos.
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
DOP2017000073A (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CL2015002835A1 (es) Nuevos derivados de piridina
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4